Skip to main content
Book a demo

Run repeatable research in your team’s format.

Apply your instructions and templates to new assets and markets, on demand or on a schedule.

Book a demo
Saved workflow

Refresh our trial tracker.

Every Monday · 8:00 AM
  1. 01Check the registry and protocol.
  2. 02Compare with the previous run.
  3. 03Update this tracker with sources.
Update the existing workbook
trial_design_tracker.xlsxUpdated

Trial design tracker

Week 3
The same illustrative trial tracker built in week one and updated in weeks two and three.
RowStudy detailCurrent assessmentSource
1Study phasePhase 3Trial registry
2Primary endpointResponse at week 24Protocol v2
3Target enrollment240 participants360 participants2Registry update
Trial designSourcesRun history
² Registry update: enrollment increased from 240 to 360.

Same tracker, updated each week.

Illustrative trial data

Build the workflow from an example deliverable.

Attach a template or prior deliverable, define the assignment, and refine the research steps Maven proposes.

Set the research criteria

Specify the scope, assessment questions, and source preferences, with your files and custom data connectors.

Reuse the format

Apply your presentation, report, or spreadsheet format to the next asset, market, or project.

“Make this review weekly. Follow our asset list, use our market notes, and keep our slide format.”

Your deliverableWord, PowerPoint, or ExcelLast review.pptx
Your scopeAsset roster.xlsx
Your contextMarket notes · Connector
Weekly access reviewWorkflow built

Build the review in our presentation template.

01
Funding by therapy
02
Eligible population
03
Access-model assumptions

access_review.pptx

Every Monday · 8:00 AMRun on demand, too
Maven live intelligenceYour connected data

See the research in your team’s format.

Maven finds and assesses the evidence, drafts the deliverable, and carries open questions into the next review.

Your format. Completed research.
singapore_access_review.pptxEditable PowerPoint
Market access / Singapore01

Funded access differs
by therapy.

Atopic dermatitis · Four-therapy review

01Funding comparison

Medication Assistance Fund¹

  • AbrocitinibRecommended
  • BaricitinibNot funded for AD
  • UpadacitinibNot funded for AD
  • DupilumabNot funded for AD

02Eligible population

Moderate-to-severe ADPrior systemic
therapy required.¹

Inadequate response, intolerance, or contraindication to at least one systemic therapy.

03Planning implication

Size the eligible population,
not the whole AD market.

¹ ACE guidance · 2 Jan 2024 · p. 1Additional prescribing criteria apply.

Expand what your team can take on.

  1. Investigate more of the opportunity set.

  2. Make expertise a shared team asset.

  3. Arrive at the review with research in hand.

See what your team could take on next.

Request a trial